Therapeutic approaches to secondary progressive multiple sclerosis

Abstract

Get full access to this article

View all access options for this article.

References

European Study Group on Interferon Beta-1b in Secondary Progressive MS. Placebo-controlled multicenter randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis . Lancet 1998; 352: 1491-1497 .

Goodkin, DE , et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis . Annals of Neurology 1995; 37: 30-40 .

Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives . Brain 1997; 120(Pt 5): 865-916 .

Noseworthy JH , Vandervoort MK , Penman M , et al. Cyclophosphamide and plasma exchange in multiple sclerosis . Lancet 1991; 337: 1540-1541 .

Weiner, HL , et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group . Neurology 1993; 43: 910-918 .

Rice GPA for the Cladribine Clinical Study Group ; and Filippi M , Comi G for the Cladribine MRI Study Group . Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial . Neurology 2000; 54: 1145-1155 .